Dr. Örn Almarsson is an established innovator of formulation design and drug development across delivery platforms enabling pharmaceutical products. Prior to founding Axelyf, Örn made significant contributions in companies including Moderna, Lyndra, Alkermes, Transform Pharmaceuticals Inc. of Lexington Massachusetts, a company specializing in small-molecule drug form and formulation, and Merck, where he started his industry career in the mid 1990s.

Örn is co-author on more than 70 scientific publications, over 60 patents and 3 book chapters. He is a visiting fellow at the UNSW RNA center in Sydney, Australia, and SSPC, an industry-academia consortium in Ireland. Örn holds a Ph.D. in bioorganic chemistry from the University of California, and a B.Sc. in chemistry from the University of Iceland. Before joining industry, he was a post-doctoral associate at MIT.